Acelyrin files to go public in rare sign of biotech IPO
California biotech Acelyrin has filed to go public, a rare attempt to access the stock markets after a year of stock declines and cutbacks across the industry.
Acelyrin was founded by veterans of Horizon Therapeutics in 2020, and in-licenses drugs or acquires their owners, then funds their development. The startup raised a $300 million Series C last fall, on top of a $250 million Series B in 2021. It was valued at $800 million after the latest round, according to PitchBook.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.